Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4635 Comparison of 18F-DOPA PET/CT and 68Ga-DOTATOC PET/CT and their impact on response to PRRT in midgut neuroendocrine tumours

Introduction: 18F-DOPA PET/CT is a powerful diagnostic test for assessing tumour burden in midgut neuroendocrine tumours (NETs). 68Ga-DOTATOC PET/CT is required for patient selection for PRRT.

Conference:

Presenting Author: Longo M

Authors: Longo M, Coccarelli A, Henry T, Kamoun T, Morbelli S,

Keywords: F-DOPA, Ga-DOTATOC, PRRT, midgut,

#4304 Co-targeting the Endocannabinoid System (ES) and mTOR in NEN potentiates their anti-tumour effect via unique metabolic changes

Introduction: The current treatment of neuroendocrine neoplasms (NEN) has limited efficacy, highlighting the need for novel therapeutic approaches. We have previously shown the potential therapeutic benefit when combining ES blocking with Everolimus (Eve).

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Kogot-Levin A, Abramovich I, Agranovich B, Polak D,

Keywords: Neuroendocrine neoplasm, Endocannabinoid system, Everolimus, metabolic Changes, metabolomics,

#4051 TECANT ERA PerMed study – Somatostatin receptor antagonists as a new sensitive diagnostic tool for reliable assessment of the SSTR status in neuroendocrine neoplasms

Introduction: The radiolabelled somatostatin receptors (SSTR) agonist development was a milestone in the management of neuroendocrine tumors (NEN), however the SSTR antagonist recognize more binding sites on NEN cells which should improve the diagnostic efficacy. The development of technetium-99m based radiopharmaceuticals should improve access to this clinically feasible diagnostic tool.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Virgolini I, Lezaic L, Decristoforo C, Kolenc P,

Keywords: NET, SSTR antagonist, SPECT/CT, SSTR, TECANT, [99mTc]Tc-TECANT1,

#3664 Cannabis and endocannabinoid system modulation as novel strategies to improve conventional treatment outcomes and overcome drug resistance in neuroendocrine neoplasms in-vitro & in-vivo models

Introduction: NENs are treated with systemic therapies with limited non-curable efficacy due to development of drug resistance (DR). While cannabis and its extracts (cannabinoids, CE) are mostly used for their palliation properties, increasing evidence suggests an anticancer trait via several cellular pathways. Limited data exist on cannabis and the endocannabinoid system (ECS) in NENs and their impact on the development of DR.

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel- Polak S, Polak D, Drier Y, Grozinsky-Glasberg S,

Keywords: neuroendocrine neoplasm, cannabinoids, cannabis extracts, endocannabinoid system, endocannabinoid receptors, everolimus,